NDC 72266-121 Levoleucovorin

Levoleucovorin

NDC Product Code 72266-121

NDC Product Information

Levoleucovorin with NDC 72266-121 is a a human prescription drug product labeled by Fosun Pharma Usa Inc.. The generic name of Levoleucovorin is levoleucovorin. The product's dosage form is injection and is administered via intravenous form.

Labeler Name: Fosun Pharma Usa Inc.

Dosage Form: Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Levoleucovorin Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • LEVOLEUCOVORIN CALCIUM 10 mg/mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • SODIUM CHLORIDE (UNII: 451W47IQ8X)
  • SODIUM HYDROXIDE (UNII: 55X04QC32I)
  • WATER (UNII: 059QF0KO0R)
  • SODIUM CHLORIDE (UNII: 451W47IQ8X)
  • SODIUM HYDROXIDE (UNII: 55X04QC32I)
  • WATER (UNII: 059QF0KO0R)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Folate Analog - [EPC] (Established Pharmacologic Class)
  • Folic Acid - [CS]

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Fosun Pharma Usa Inc.
Labeler Code: 72266
FDA Application Number: ANDA210892 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 06-25-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Levoleucovorin Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

  • Levoleucovorin injection is a folate analog.Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in osteosarcoma.Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.Levoleucovorin injection is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

1.1 Limitations Of Use

  • Levoleucovorin injection is not approved for pernicious anemia and megaloblastic anemias secondary to the lack of vitamin B
  • 12.Improper use may cause a hematologic remission while neurologic manifestations continue to progress.

2.1 Administration Guidelines

Levoleucovorin injection is dosed at


one-half the usual dose of racemic


d,l-leucovorin.


Levoleucovorin injection is indicated for intravenous administration only.Do not administer intrathecally.

2.2 Co-Administration Of Levoleucovorin Injection With Other Agents

Due to the risk of precipitation, do not co-administer Levoleucovorin injection with other agents in the same admixture.

2.3 Levoleucovorin Injection Rescue After High-Dose Methotrexate Therapy

The recommendations for Levoleucovorin injection rescue are based on a methotrexate dose of 12 grams/m


2 administered by intravenous infusion over 4 hours(see methotrexate package insert for full prescribing information).Levoleucovorin injection rescue at a dose of 7.5 mg(approximately 5 mg/m


2)every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion.


Serum creatinine and methotrexate levels should be determined at least once daily. Levoleucovorin injection administration, hydration, and urinary alkalinization (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10


-8 M (0.05 micromolar). The Levoleucovorin injection dose should be adjusted or rescue extended based on the following guidelines.


Table 1 Guidelines for Levoleucovorin injection Dosage and Administration


Clinical Situation


Laboratory Findings


Levoleucovorin injection Dosage and Duration


Normal Methotrexate Elimination


Serum methotrexate level approximately 10 micromolar at  24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours


7.5 mg IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).


Delayed Late Methotrexate Elimination


Serum methotrexate level remaining above 0.2 micromolar at 72 hours, and more than 0.05 micromolar at 96 hours after administration.


Continue 7.5 mg IV q 6 hours, until methotrexate level is less than 0.05 micromolar.


Delayed Early Methotrexate Elimination and/or Evidence of Acute Renal Injury


Serum methotrexate level of


50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase from 0.5 mg/dL to a level of 1 mg/dL or more).


75 mg IV q 3 hours until methotrexate level is less than 1 micromolar; then 7.5 mg IV q 3 hours until methotrexate level is less than 0.05 micromolar.


Patients who experience delayed early methotrexate elimination are likely to develop reversible renal failure. In addition to appropriate levoleucovorin injection therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the renal failure has resolved.


Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe than the abnormalities described in the table above. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, Levoleucovorin injection rescue should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed. Delayed methotrexate excretion may be caused by accumulation in a third space fluid collection (i.e., ascites, pleural effusion), renal insufficiency, or inadequate hydration. Under such circumstances, higher doses of levoleucovorin injection or prolonged administration may be indicated.Although levoleucovorin injection may ameliorate the hematologic toxicity associated with high-dose methotrexate, levoleucovorin injection has no effect on other established toxicities of methotrexate such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney.

2.4 Dosing Recommendations For Inadvertent Methotrexate Overdosage

Levoleucovorin injection rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is delayed excretion. As the time interval between antifolate administration [e.g., methotrexate] and levoleucovorin injection rescue increases, levoleucovorin injection effectiveness in counteracting toxicity may decrease. Levoleucovorin injection 7.5 mg(approximately 5 mg/m


2 ) should be administered IV every 6 hours until the serum methotrexate level is less than 10


-8 M. Serum creatinine and methotrexate levels should be determined at 24 hour intervals. If the 24 hour serum creatinine has increased 50% over baseline or if the 24 hour methotrexate level is greater than 5 x 10


-6 M or the 48 hour level is greater than 9 x 10


-7 M, the dose of levoleucovorin injection should be increased to 50 mg/m


2 IV every 3 hours until the methotrexate level is less than 10


-8 M. Hydration (3 L/day) and urinary alkalinization with NaHCO3 should be employed concomitantly. The bicarbonate dose should be adjusted to maintain the urine pH at 7.0 or greater.

2.5 Levoleucovorin Injection Administration In Combination With 5-Fluorouracil(5-Fu)

  • The following regimens have been used historically for the treatment of colorectal cancer:Levoleucovorin injection is administered at 100 mg/m
  • 2 by slow intravenous injection over a minimum of 3 minutes, followed by 5-FU at 370 mg/m
  • 2 by intravenous injection.
  • Levoleucovorin injection is administered at 10 mg/m
  • 2 by intravenous injection followed by 5-FU at 425 mg/m
  • 2 by intravenous injection.
  • 5-FU and levoleucovorin injection should be administered separately to avoid the formation of a precipitate.Treatment is repeated daily for five days. This five-day treatment course may be repeated at 4 week (28-day) intervals, for 2 courses and then repeated at 4 to 5 week (28 to 35 day) intervals provided that the patient has completely recovered from the toxic effects of the prior treatment course.In subsequent treatment courses, the dosage of 5-FU should be adjusted based on patient tolerance of the prior treatment course. The daily dosage of 5-FU should be reduced by 20% for patients who experienced moderate hematologic or gastrointestinal toxicity in the prior treatment course, and by 30% for patients who experienced severe toxicity. For patients who experienced no toxicity in the prior treatment course, 5-FU dosage may be increased by 10%. Levoleucovorin injection dosages are not adjusted for toxicity.

2.6 Reconstitution And Infusion Instructions

  • Levoleucovorin InjectionLevoleucovorin injection contains no preservative. Observe strict aseptic technique during reconstitution of the drug product. Levoleucovorin injection solutions may be further diluted to concentrations of 0.5 mg/mL in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. The diluted solution using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be held at room temperature for not more than 4 hours. Visually inspect the diluted solution for particulate matter and discoloration, prior to administration. CAUTION: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if cloudiness or precipitate is observed. No more than 16 mL of levoleucovorin Injection (160 mg of levoleucovorin) should be injected intravenously per minute, because of the calcium content of the levoleucovorin solution.

3 Dosage Forms And Strengths

Levoleucovorin Injection, 175 mg is supplied in a single-dose vial containing 17.5 mL sterile solution. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.Levoleucovorin Injection, 250 mg is supplied in a single-dose vial containing 25 mL sterile solution. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.

4 Contraindications

Levoleucovorin injection is contraindicated for patients who have had previous allergic reactions attributed to folic acid or folinic acid.

5.1 Rate Of Administration

Because of the Ca


++ content of the levoleucovorin solution, no more than 16 mL(160 mg of levoleucovorin) should be injected intravenously per minute.

5.2 Potential For Enhanced Toxicity With 5-Fluorouracil

Levoleucovorin injection enhances the toxicity of 5-fluorouracil. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly


d,l-leucovorin and 5-fluorouracil. When these drugs are administered concurrently in the palliative treatment of advanced colorectal cancer, the dosage of 5-FU must be lower than usually administered. Although the toxicities observed in patients treated with the combination of levoleucovorin injection and 5-FU are qualitatively similar to those observed with 5-FU alone, gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more commonly and may be of greater severity and of prolonged duration in patients treated with the combination.


In the first Mayo/NCCTG controlled trial, toxicity, primarily gastrointestinal, resulted in 7% of patients requiring hospitalization when treated with 5-FU alone or 5-FU in combination with 200 mg/m


2 of


d,l-leucovorin and 20% when treated with 5-FU in combination with 20 mg/m


2 of


d,l-leucovorin. In the second Mayo/NCCTG trial, hospitalizations related to treatment toxicity also appeared to occur more often in patients treated with the low dose


d,l-leucovorin/5-FU combination than in patients treated with the high dose combination – 11% versus 3%. Therapy with levoleucovorin injection and 5-FU must not be initiated or continued in patients who have symptoms of gastrointestinal toxicity of any severity, until those symptoms have completely resolved. Patients with diarrhea must be monitored with particular care until the diarrhea has resolved, as rapid clinical deterioration leading to death can occur. In an additional study utilizing higher weekly doses of 5-FU and


d,l-leucovorin, elderly and/or debilitated patients were found to be at greater risk for severe gastrointestinal toxicity.


Seizures and/or syncope have been reported rarely in cancer patients receiving


d,l-leucovorin, usually in association with fluoropyrimidine administration, and most commonly in those with CNS metastases or other predisposing factors. However, a causal relationship has not been established.

5.3 Potential For Interaction With Trimethoprim-Sulfamethoxazole

The concomitant use of


d,l-leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis carinii pneumonia in patients with HIV infection was associated with increased rates of treatment failure and morbidity in a placebo-controlled study.

6.1 Clinical Studies In High-Dose Methotrexate Therapy

Since clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following table presents the frequency of adverse reactions which occurred during the administration of 58 courses of high-dose methotrexate 12 grams/m


2 followed by Levoleucovorin injection rescue for osteosarcoma in 16 patients age 6 to 21. Most patients received levoleucovorin injection 7.5 mg every 6 hours for 60 hours or longer beginning 24 hours after completion of methotrexate.


Table 2 Adverse Reactions with High-Dose Methotrexate Therapy


Body System/ Adverse Reactions


Number (%) of Patients with Adverse Reactions (N =16)


Number (%) of Courses with Adverse Reactions (N = 58)


All


Grade 3+


All


Grade 3+


Gastrointestinal


Stomatitis


6 (37.5)


1 (6.3)


10 (17.2)


1 (1.7)


Vomiting


6 (37.5)


0


14 (24.1)


0


Nausea


3 (18.8)


0


3 (5.2)


0


Diarrhea


1 (6.3)


0


1 (1.7)


0


Dyspepsia


1 (6.3)


0


1 (1.7)


0


Typhlitis


1 (6.3)


1 (6.3)


1 (1.7)


1 (1.7)


Respiratory


Dyspnea


1 (6.3)


0


1 (1.7)


0


Skin and Appendages


Dermatitis


1 (6.3)


0


1 (1.7)


0


Other


Confusion


1 (6.3)


0


1 (1.7)


0


Neuropathy


1 (6.3)


0


1 (1.7)


0


Renal function abnormal


1 (6.3)


0


3 (5.2)


0


Taste perversion


1 (6.3)


0


1 (1.7)


0


Total number of patients


9 (56.3)


2 (12.5)


Total number of courses


25 (43.1)


2 (3.4)


The incidence of adverse reactions may be underestimated because not all patients were fully evaluable for toxicity for all cycles in the clinical trials. Leukopenia and thrombocytopenia were observed, but could not be attributed to high-dose methotrexate with levoleucovorin injection rescue because patients were receiving other myelosuppressive chemotherapy.

6.2 Clinical Studies In Combination With 5-Fu In Colorectal Cancer

A randomized controlled trial conducted by the North Central Cancer Treatment Group (NCCTG) in patients with advanced colorectal cancer failed to show superiority of a regimen of 5-FU + levoleucovorin to 5-FU +


d,l-leucovorin in overall survival. Patients were randomized to 5-FU 370 mg/m


2 intravenously and levoleucovorin 100 mg/m


2 intravenously, both daily for 5 days, or with 5-FU 370 mg/m


2 intravenously and


d,l-leucovorin 200 mg/m


2 intravenously, both daily for 5 days. Treatment was repeated week 4 and week 8, and then every 5 weeks until disease progression or unacceptable toxicity. The following table presents the most frequent adverse reactions which occurred in patients in the 2 treatment arms.


Table 3 Adverse Reactions Occurring in ≥ 10% of Patients in Either ArmAdverse Reaction Levoleucovorin/5FU n=318 d,l-Leucovorin/5FU n=307


Adverse Event N (%)


Grade 1-4


Grade 3-4


Grade 1-4


Grade 3-4


Gastrointestinal


Stomatitis


229 (72%)


37 (12%)


221 (72%)


44 (14%)


Diarrhea


222 (70%)


61 (19%)


201 (65%)


51 (17%)


Nausea


197 (62%)


25 (8%)


186 (61%)


26 (8%)


Vomiting


128 (40%)


17 (5%)


114 (37%)


18 (6%)


Abdominal Pain


145 (14%)


10 (3%)


57 (19%)


10 (3%)


General Disorders


Asthenia/Fatigue/Malaise


91 (29%)


15 (5%)


99 (32%)


34 (11%)


Metabolism and Nutrition


Anorexia/Decreased Appetite


76 (24%)


13 (4%)


77 (25%)


5 (2%)


Skin Disorders


Dermatitis


91 (29%)


3 (1%)


86 (28%)


4 (1%)


Alopecia


83 (26%)


1 (0.3%)


87 (28%)


3 (1%)


1Includes abdominal pain, upper abdominal pain, lower abdominal pain, and abdominal tenderness

6.3 Postmarketing Experience

Since adverse reactions from spontaneous reports are provided voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Spontaneously reported adverse reactions collected by the WHO Collaborating Center for International Drug Monitoring in Uppsala Sweden have yielded seven cases where levoleucovorin was administered with a regimen of methotrexate. The events were dyspnea, pruritus, rash, temperature change and rigors. For 217 adverse reactions (108 reports) where levoleucovorin was a suspected or interacting medication, there were 40 occurrences of “possible allergic reactions.” In an analysis where calcium levoleucovorin injection was reported as the primary suspect drug and fluorouracil (FU) was reported as a concomitant medication, possible allergic reactions were reported among 47 cases (67 events).

7 Drug Interactions

Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible children. It is not known whether folinic acid has the same effects.However, both folic and folinic acids share some common metabolic pathways. Caution should be taken when taking folinic acid in combination with anticonvulsant drugs.Preliminary human studies have shown that small quantities of systemically administered leucovorin enter the CSF, primarily as its major metabolite, 5-methyltetrahydrofolate(5-MTHFA). In humans, the CSF levels of 5-MTHFA remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.Levoleucovorin injection increases the toxicity of 5-fluorouracil


[see Warnings and Precautions (5.2)].

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with levoleucovorin injection. It is not known whether levoleucovorin injection can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Levoleucovorin injection should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from levoleucovorin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

[See Clinical Studies (14)]

8.5 Geriatric Use

Clinical studies of levoleucovorin injection in the treatment of osteosarcoma did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. In the NCCTG clinical trial of levoleucovorin injection in combination with 5-FU in advanced colorectal cancer, adverse reactions were consistent with 5-FU related toxicity and were similar for patients age 65 and older and for patients younger than age 65.

10 Overdosage

No data are available for overdosage with levoleucovorin.

11 Description

Levoleucovorin is the levo isomeric form of racemic


d,l-leucovorin, present as the calcium salt. Levoleucovorin is the pharmacologically active isomer of leucovorin [(6-S)-leucovorin].


Levoleucovorin Injection contains levoleucovorin calcium, which is one of several active, chemically reduced derivatives of folic acid. It is useful as antidote to the inhibition of dihydrofolate reductase by methotrexate. This compound has the chemical designation calcium (6S)-N-{4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl}­L-glutamate pentahydrate.The molecular weight is 601.6 and the structural formula is:Its molecular formula is C


20H


21CaN


7O


7  . 5 H


20.


Levoleucovorin Injection is supplied as a sterile solution of either 175 mg levoleucovorin in 17.5 ml or  250 mg levoleucovorin in 25 mL. Each mL contains levoleucovorin calcium pentahydrate equivalent to   10 mg levoleucovorin and 8.3 mg sodium chloride. Sodium hydroxide is used for pH adjustment to pH 8.0 (6.5 to 8.5).

12.1 Mechanism Of Action

12.1.1 Levoleucovorin effects during high-dose methotrexate therapy Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “onecarbon” moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.12.1.2 Levoleucovorin effects in combination with 5-fluorouracil Levoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as 5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to and inhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylate synthase and thereby enhances the inhibition of this enzyme.

12.2 Pharmacodynamics

Levoleucovorin is actively and passively transported across cell membranes. In vivo, levoleucovorin is converted to 5-methyltetrahydrofolic acid (5-methyl-THF), the primary circulating form of active reduced folate. Levoleucovorin and 5-methyl-THF are polyglutamated intracellularly by the enzyme folylpolyglutamate synthetase. Folylpolyglutamates are active and participate in biochemical pathways that require reduced folate.

12.3 Pharmacokinetics

The pharmacokinetics of levoleucovorin after intravenous administration of a 15 mg dose was studied in healthy male volunteers. After rapid intravenous administration, serum total tetrahydrofolate (total-THF) concentrations reached a mean peak of 1722 ng/mL. Serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations reached a mean peak of 275 ng/mL and the mean time to peak was 0.9 hours. The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8 tetrahydrofolate was 5.1 and 6.8 hours, respectively. A pharmacokinetic study was conducted in 40 healthy subjects who received a single intravenous dose of either levoleucovorin (200 mg/m


2) or racemic


d,l-leucovorin(400 mg/m


2), each administered as a 2-hour infusion in a crossover design. Results indicate that the 90% confidence interval for the geometric mean ratios for both AUC


0-inf and C


max were within the standard limit of 80 to 125% for both


l-leucovorin and


l-5-methyl-THF. Therefore, the exposure to


l-leucovorin and 5-methyl-THF(AUC


0-inf and C


max)was comparable whether it was administered as levoleucovorin or as


d,l-leucovorin. The geometric mean AUC


0-inf values for levoleucovorin were 30719 ng.h/mL and 31296 ng.h/mL for levoleucovorin and


d,l-leucovorin, respectively. The geometric mean C


max values for levoleucovorin were 10895 ng/mL and 11301 ng/ mL for levoleucovorin and


d,l-leucovorin, respectively. The geometric mean AUC


0-inf values for 5-methyl-THF were 52105 ng.h/mL and 50137 ng.h/mL for levoleucovorin and


d,l-leucovorin, respectively. The geometric mean C


max values for 5-methyl-THF were 4930 ng/mL and 4658 ng/mL for levoleucovorin and


d,l-leucovorin, respectively.


Use of Levoleucovorin in combination with 5-fluorouracil A published cross study comparison showed that the mean dose-normalized steady-state plasma concentrations for both levoleucovorin and 5-methyl-THF were comparable whether 5-FU (370 mg/m


2/day IV bolus) was given in combination with levoleucovorin (250 mg/m


2 and 1000 mg/m


2 as a continuous IV infusion for 5.5 days, N=9) or in combination with


d,l-leucovorin (500 mg/m


2 as a continuous IV infusion for 5.5 days, N=6).

13.1 Carcinogenesis, Mutagenesis,  Impairment Of Fertility

No studies have been conducted to evaluate the potential of levoleucovorin for carcinogenesis, mutagenesis and impairment of fertility.

13.2 Animal Toxicology And/Or Pharmacology

The acute intravenous LD


50 values in adult mice and rats were 575 mg/kg (1725 mg/m


2) and 378 mg/kg (2268 mg/m


2), respectively. Signs of sedation, tremors, reduced motor activity, prostration, labored breathing, and/or convulsion were observed in these studies. Anticipated human dose for each administration is approximately 5 mg/m


2 for high-dose methotrexate therapy which represents a 3-log safety margin.

14.1 High-Dose Methotrexate Therapy

The safety and efficacy of levoleucovorin rescue following high-dose methotrexate were evaluated in 16 patients age 6 to 21 who received 58 courses of therapy for osteogenic sarcoma. High-dose methotrexate was one component of several different combination chemotherapy regimens evaluated across several trials. Methotrexate 12 g/m


2 IV over 4 hours was administered to 13 patients, who received levoleucovorin 7.5 mg every 6 hours for 60 hours or longer beginning 24 hours after completion of methotrexate. Three patients received methotrexate 12.5 g/m


2 IV over 6 hours, followed by levoleucovorin 7.5 mg every 3 hours for 18 doses beginning 12 hours after completion of methotrexate. The mean number of levoleucovorin doses per course was 18.2 and the mean total dose per course was 350 mg. The efficacy of levoleucovorin rescue following high-dose methotrexate was based on the adverse reaction profile.


[See Adverse Reactions (6)]

14.2 Combination With 5-Fu In Colorectal Cancer

In a randomized clinical study conducted by the Mayo Clinic and the North Central Cancer Treatment Group (Mayo/NCCTG) in patients with advanced metastatic colorectal cancer, three treatment regimens were compared:


d,l-leucovorin (LV) 200 mg/m


2 and 5-fluorouracil (5-FU) 370 mg/m


2 versus LV 20 mg/m


2 and 5-FU 425 mg/m


2 versus 5-FU 500 mg/m


2. All drugs were administered by slow intravenous infusion daily for 5 days repeated every 28 to 35 days. Response rates were 26% (p=0.04 versus 5-FU alone), 43% (p=0.001 versus 5-FU alone) and 10% for the high dose leucovorin, low dose leucovorin and 5-FU alone groups, respectively. Respective median survival times were 12.2 months (p=0.037), 12 months (p=0.050), and 7.7 months. The low dose LV regimen gave a statistically significant improvement in weight gain of more than 5%, relief of symptoms, and improvement in performance status. The high dose LV regimen gave a statistically significant improvement in performance status and trended toward improvement in weight gain and in relief of symptoms but these were not statistically significant.


In a second Mayo/NCCTG randomized clinical study the 5-FU alone arm was replaced by a regimen of sequentially administered methotrexate (MTX), 5-FU, and LV. Response rates with LV 200 mg/m


2 and 5-FU 370 mg/m


2 versus LV 20 mg/m


2 and 5-FU 425 mg/m


2 versus sequential MTX and 5-FU and LV were respectively 31% (p≤0.01), 42% (p≤0.01), and 14%. Respective median survival times were 12.7 months (p≤0.04), 12.7 months (p≤0.01), and 8.4 months. No statistically significant difference in weight gain of more than 5% or in improvement in performance status was seen between the treatment arms.


A randomized controlled trial conducted by the NCCTG in patients with advanced metastatic colorectal cancer failed to show superiority of a regimen of 5-FU + levoleucovorin to 5-FU +


d,l-leucovorin in overall survival. Patients were randomized to 5-FU 370 mg/m


2 intravenously and levoleucovorin 100 mg/m


2 intravenously, both daily for 5 days, or with 5-FU 370 mg/m


2 intravenously and


d,l-leucovorin 200 mg/m


2 intravenously, both daily for 5 days. Treatment was repeated week 4 and week 8, and then every 5 weeks until disease progression or unacceptable toxicity.


Levoleucovorin is dosed at


one-half the usual dose of racemic


d,l-leucovorin.

16 How Supplied/Storage And Handling

Levoleucovorin Injection, 175 mg contains 17.5 mL sterile clear pale yellow color solution in a single-dose vial. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.


NDC 72266-120-01


175 mg/17.5 mL solution - carton containing one single-dose vial


Levoleucovorin Injection, 250 mg contains 25 mL sterile clear pale yellow color solution in a single-dose vial. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.


NDC 72266-121-01


250 mg/25 mL solution - carton containing one single-dose vial


Store in refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Store in carton until contents are used.Trademarks are the property of their respective owners.


Distributed by:Fosun Pharma USA Inc.


Princeton, NJ 08540


Made in India


January 2019

* Please review the disclaimer below.

Previous Code
72266-120
Next Code
72266-122